Back to Search
Start Over
A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients.
- Source :
-
Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2020 Sep 28; Vol. 10 (10). Date of Electronic Publication: 2020 Sep 28. - Publication Year :
- 2020
-
Abstract
- Background: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim of the study was to describe the LB practice for EGFR detection in North Eastern Italy.<br />Methods: we conducted a multi-regional survey on ctDNA testing practices in lung cancer patients.<br />Results: Median time from blood collection to plasma separation was 50 min (20-120 min), median time from plasma extraction to ctDNA analysis was 24 h (30 min-5 days) and median turnaround time was 24 h (6 h-5 days). Four hundred and seventy five patients and 654 samples were tested. One hundred and ninety-two patients were tested at diagnosis, with 16% EGFR mutation rate. Among the 283 patients tested at disease progression, 35% were T790M+. Main differences in LB results between 2017 and 2018 were the number of LBs performed for each patient at disease progression (2.88 vs. 1.2, respectively) and the percentage of T790M+ patients (61% vs. 26%).
Details
- Language :
- English
- ISSN :
- 2075-4418
- Volume :
- 10
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Diagnostics (Basel, Switzerland)
- Publication Type :
- Academic Journal
- Accession number :
- 32998450
- Full Text :
- https://doi.org/10.3390/diagnostics10100765